Innate Pharma Shares Rise after Sanofi Exercises Licensing Option
By Dean Seal
Innate Pharma's American depositary receipts rose after the company said Sanofi had exercised its option to license a natural killer cell engager program in solid tumors from Innate's ANKET platform.
The stock was up 14% at $2.79 in premarket trading. Shares had fallen by a third year-to-date when the market closed Monday.
The biopharmaceutical company said early Tuesday morning that the licensing comes pursuant to the terms of a research collaboration and license agreement signed in December 2022.
After a research collaboration period, Sanofi will be responsible for development, manufacturing and commercialization, Innate said, adding that Sanofi still has the option under the license agreement for one additional ANKET target.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 19, 2023 07:13 ET (12:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth